/EVGN

EVGN Stock - Evogene Ltd.

Q: What is the analyst price target for EVGN?

Analyst price target information is not currently available for EVGN.

Q: What is EVGN's market cap?

Market capitalization information is not currently available for EVGN.

Healthcare|Biotechnology|NASDAQ

$1.02+3.20%

+$0.03 (+3.20%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+243.2%upside

Target: $3.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for EVGN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.58

52W High$2.42

52W Low$0.95

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$8.51M	$5.64M	$1.68M	$930,000	$1.04M
Gross Profit	$3.39M	$1.40M	$-1,774,000	$-2,071,000	$-2,261,000
Gross Margin	39.8%	24.8%	-105.9%	-222.7%	-217.4%
Operating Income	$-21,734,000	$-26,391,000	$-29,715,000	$-31,490,000	$-26,835,000
Net Income	$-16,485,000	$-23,879,000	$-26,638,000	$-27,793,000	$-23,374,000
Net Margin	-193.7%	-423.4%	-1590.3%	-2988.5%	-2247.5%
EPS	$-2.89	$-5.23	$-6.46	$-0.68	$-0.64

Company Overview

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Visit Website

Earnings History & Surprises

EVGN

Beat Rate

56%

Last 18 quarters

Avg Surprise

-116.9%

EPS vs Estimate

Beats / Misses

10/8

Last 12 quarters

Latest EPS

$-0.31

Q4 2025

EPS Surprise History

Q1 24

+7.1%

$-1.30vs$-1.40

Q2 24

-788.9%

$-0.80vs$-0.09

Q3 24

-783.3%

$-1.06vs$-0.12

Q4 24

-29.7%

$-1.31vs$-1.01

Q1 25

+108.3%

$0.06vs$-0.72

Q2 25

+39.2%

$-0.38vs$-0.63

Q3 25

+0.8%

$-0.62vs$-0.63

Q4 25

-19.2%

$-0.31vs$-0.26

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 19, 2026	—	—	—	—
Q1 2026	Mar 4, 2026	—	—	—	—
Q4 2025	Nov 20, 2025	$-0.26	$-0.31	-19.2%	✗ MISS
Q3 2025	Aug 19, 2025	$-0.63	$-0.62	+0.8%	✓ BEAT
Q2 2025	May 21, 2025	$-0.63	$-0.38	+39.2%	✓ BEAT
Q1 2025	Mar 6, 2025	$-0.72	$0.06	+108.3%	✓ BEAT
Q4 2024	Nov 21, 2024	$-1.01	$-1.31	-29.7%	✗ MISS
Q3 2024	Aug 22, 2024	$-0.12	$-1.06	-783.3%	✗ MISS
Q2 2024	May 23, 2024	$-0.09	$-0.80	-788.9%	✗ MISS
Q1 2024	Mar 7, 2024	$-1.40	$-1.30	+7.1%	✓ BEAT
Q4 2023	Nov 15, 2023	$-1.70	$-0.80	+52.9%	✓ BEAT
Q3 2023	Aug 17, 2023	$-1.90	$-1.70	+10.5%	✓ BEAT
Q2 2023	May 18, 2023	$-1.60	$-1.50	+6.3%	✓ BEAT
Q1 2023	Mar 9, 2023	$-2.10	$-0.70	+66.7%	✓ BEAT
Q4 2022	Nov 17, 2022	$-2.00	$-1.60	+20.0%	✓ BEAT
Q3 2022	Aug 31, 2022	$-1.80	$-2.10	-16.7%	✗ MISS
Q2 2022	May 26, 2022	$-1.40	$-2.00	-42.9%	✗ MISS
Q1 2022	Mar 10, 2022	$-2.00	$-1.80	+10.0%	✓ BEAT
Q4 2021	Nov 17, 2021	$-1.70	$-1.90	-11.8%	✗ MISS
Q3 2021	Aug 11, 2021	$-0.18	$-1.50	-733.3%	✗ MISS